(R)-Hydroxytolterodine-d14 is deuterated labeled Desfesoterodine (HY-76569). Desfesoterodine (PNU-200577) is a potent and selective muscarinic receptor (mAChR) antagonist with a KB and a pA2 of 0.84 nM and 9.14, respectively[1]. Desfesoterodine is a major pharmacologically active metabolite of Tolterodine (PNU-200583; HY-A0024) and Fesoterodine (HY-70053)[2][3]. Desfesoterodine improves cerebral infarction induced detrusor overactivity in rats[4].

(R)-LW-Srci-8 is a selective covalent inhibitor of c?Src (IC50= 35.83 nM) that disrupts the autophosphorylation of c?Src by targeting its autophosphorylation site (Y419)[1].

(R)-ML375 ((R)-VU0483253) is an enantiomer of ML375 (HY-12567). (R)-ML375 is devoid of M5 mAChR activity (hM5, IC50>30 μM)[1].

(R)-ML375 ((R)-VU0483253) is an enantiomer of ML375 (HY-12567). (R)-ML375 is devoid of M5 mAChR activity (hM5, IC50>30 μM)[1].

(R)-ML375 ((R)-VU0483253) is an enantiomer of ML375 (HY-12567). (R)-ML375 is devoid of M5 mAChR activity (hM5, IC50>30 μM)[1].

(R)-ML375 ((R)-VU0483253) is an enantiomer of ML375 (HY-12567). (R)-ML375 is devoid of M5 mAChR activity (hM5, IC50>30 μM)[1].

(R)-ML375 ((R)-VU0483253) is an enantiomer of ML375 (HY-12567). (R)-ML375 is devoid of M5 mAChR activity (hM5, IC50>30 μM)[1].

(R)-MPH-220 is the R isomer of MPH-220 (HY-148516). MPH-220 is a selective and orally active inhibitor of skeletal muscle myosin-2. MPH-220 enables muscle relaxation. MPH-220 is anti-spastic agent that can be used in the research of spasticity and muscle stiffness[1].

(R)-MPH-220 is the R isomer of MPH-220 (HY-148516). MPH-220 is a selective and orally active inhibitor of skeletal muscle myosin-2. MPH-220 enables muscle relaxation. MPH-220 is anti-spastic agent that can be used in the research of spasticity and muscle stiffness[1].

(R)-MPH-220 is the R isomer of MPH-220 (HY-148516). MPH-220 is a selective and orally active inhibitor of skeletal muscle myosin-2. MPH-220 enables muscle relaxation. MPH-220 is anti-spastic agent that can be used in the research of spasticity and muscle stiffness[1].

(R)-MPH-220 is the R isomer of MPH-220 (HY-148516). MPH-220 is a selective and orally active inhibitor of skeletal muscle myosin-2. MPH-220 enables muscle relaxation. MPH-220 is anti-spastic agent that can be used in the research of spasticity and muscle stiffness[1].

(R)-MrgprX2 antagonist-3 (compound E118) is an MrgprX2 antagonist extracted from patent WO2021092240A1, example E118. (R)-MrgprX2 antagonist-3 can be used for the research of inflammatory disorders of the skin[1].

(R)-N-(1-Hydroxypropan-2-yl)palmitamide (compound 24) is a substrate analog inhibitor of phospholipase A2[1].

(R)-NX-2127 (compound 28) is an orally active Bruton’s Tyrosine Kinase (Btk) degrader. (R)-NX-2127 degrades IKZF1 and IKZF3 by molecular glue interactions with the cereblon E3 ubiquitin ligase complex[1].

(R)-Palmitoyl-(2-methyl)ethanolamide (Me-PEA) is a competitive inhibitor of [3 H]-AEA metabolism with a Ki value of 6.6 μM[1].

(R)-Pantetheine-15N (Pantetheine-15N) is the 15N labeled (R)-Pantetheine (HY-126050). (R)-Pantetheine is the biosynthetic precursor to CoA[1].

(R)-Safinamide, the enantiomer of safinamide (HY-70057), can inhibit MAO-B with an IC50 value of 0.45 μM[1].

(R)-tetraMe-Tetraxetanis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. (R)-tetraMe-Tetraxetan can be used for conjugation of peptides and radionuclides.

(Rac)-BA-1049-d5 is deuterated labeled (Rac)-BA-1049.

(Rac)-Hydroxycotinine-d3 is deuterated labeled Hydroxycotinine (HY-113239). Hydroxycotinine is the main nicotine metabolite detected in smokers urine.

(Rac)-JBJ-04-125-02 acetate is the racemate of JBJ-04-125-02. JBJ-04-125-02 is a potent, selective mutagenesis, allosteric and orally active EGFR inhibitor[1].

(Rac)-JBJ-04-125-02 acetate is the racemate of JBJ-04-125-02. JBJ-04-125-02 is a potent, selective mutagenesis, allosteric and orally active EGFR inhibitor[1].

(Rac)-JBJ-04-125-02 acetate is the racemate of JBJ-04-125-02. JBJ-04-125-02 is a potent, selective mutagenesis, allosteric and orally active EGFR inhibitor[1].

(Rac)-Metanephrine (hydrochloride) is a biochemical reagent that can be used as a biological material or organic compound for life science related research[1].

(Rac)-Metanephrine (hydrochloride) is a biochemical reagent that can be used as a biological material or organic compound for life science related research[1].

(Rac)-Nebivolol-d2,15N is 15N and deuterated labeled (Rac)-Nebivolol (HY-B0203B). (Rac)-Nebivolol ((Rac)-R 065824) is a racemic isomer of Nebivolol. Nebivolol is a selective β1-adrenergic receptor antagonist with an IC50 value of 0.8 nM. Nebivolol can prevent up-regulation of Nox2/NADPH oxidase and lipoperoxidation in the early stages of ethanol-induced cardiac toxicity. Vasodilatory activity[1][2].

(Rac)-PDE4-IN-4 is the diastereomer mixture of PDE4-IN-4 (HY-115871). PDE4-IN-4 is a dual M3 (pIC50 = 10.2) antagonist-PDE4 (pIC50 = 8.8) inhibitor for the inhaled research of pulmonary diseases[1].

(RS)-G12Di-1 is a selective, covalent inhibitor of K-Ras-G12D[1].

(S,R,S)-AHPC-CO-C9-NH2 (hydrochloride) is a von Hippel-Lindau (VHL) amino building block that can be used to synthesize E3 ligase ligands required for PROTACs..

(S,R,S)-AHPC-CO-C9-NH2 (hydrochloride) is a von Hippel-Lindau (VHL) amino building block that can be used to synthesize E3 ligase ligands required for PROTACs..

(S,R,S)-AHPC-CO-C9-NH2 (hydrochloride) is a von Hippel-Lindau (VHL) amino building block that can be used to synthesize E3 ligase ligands required for PROTACs..

(S,R,S)-AHPC-CO-C9-NH2 (hydrochloride) is a von Hippel-Lindau (VHL) amino building block that can be used to synthesize E3 ligase ligands required for PROTACs..

(S,R,S)-AHPC-CO-C9-NH2 (hydrochloride) is a von Hippel-Lindau (VHL) amino building block that can be used to synthesize E3 ligase ligands required for PROTACs..

(S,S,R)-AHPC-C6-NH2 is a E3 Ligase Ligand-Linker Conjugate of HL-8 (HY-143275). HL-8 is a PROTAC molecule targeting PI3K kinase[1].

(S)-3-Amino-2-oxo-azepane (hydrochloride) is a biochemical reagent that can be used as a biological material or organic compound for life science related research[1].

(S)-3-Hydroxyhexanoyl-CoA (L-3-Hydroxyhexanoyl-CoA) is a hydroxy fatty acyl-CoA[1].

(S)-5,7-Diacetoxyflavanone is a flavanone with antimicrobial activity[1].

(S)-AL 8810 is an 11β-fluoro analog of PGF2α that acts as a potent and selective antagonist at the FP receptor. (S)-AL 8810 is the C-15 epimer of AL 8810, having the inverse, (S), or “natural” configuration at C-15 relative to AL 8810, which is 15-(R)[1].

(S)-ARI-1 is an S-enantiomer of ARI-1. ARI-1 is a ROR1 inhibitor and apoptosis inducer, used in NSCLC research[1].

(S)-ARI-1 is an S-enantiomer of ARI-1. ARI-1 is a ROR1 inhibitor and apoptosis inducer, used in NSCLC research[1].

(S)-ARI-1 is an S-enantiomer of ARI-1. ARI-1 is a ROR1 inhibitor and apoptosis inducer, used in NSCLC research[1].

(S)-CE-123 is a potent, selective, and novel atypical dopamine transporter (DAT) inhibitor with an EC50 of 2.76 μM in uptake inhibition assays conducted in HEK293 cells stably expressing human isoforms of DAT. (S)-CE-123, a Modafinil analogue, is able to penetrate the blood–brain barrier. (S)-CE-123 improves cognitive and motivational processes in experimental animals[1][2].

(S)-PF-06873600 it the S enantiomer of PF-06873600. PF-06873600 is a selective and orally bioavailable inhibitor of cyclin-dependent kinase (CDK).

(S)-PF-06873600 it the S enantiomer of PF-06873600. PF-06873600 is a selective and orally bioavailable inhibitor of cyclin-dependent kinase (CDK).

(S)-PF-06873600 it the S enantiomer of PF-06873600. PF-06873600 is a selective and orally bioavailable inhibitor of cyclin-dependent kinase (CDK).

(S)-PF-06873600 it the S enantiomer of PF-06873600. PF-06873600 is a selective and orally bioavailable inhibitor of cyclin-dependent kinase (CDK).

(S)-PF-06873600 it the S enantiomer of PF-06873600. PF-06873600 is a selective and orally bioavailable inhibitor of cyclin-dependent kinase (CDK).

(S)-GSK852 is a diastereomer of GSK852 (HY-115867). GSK852 is a BET inhibitor targeting BD2 (pIC50=7.9)[1].

(S)-GSK852 is a diastereomer of GSK852 (HY-115867). GSK852 is a BET inhibitor targeting BD2 (pIC50=7.9)[1].

(S)-GSK852 is a diastereomer of GSK852 (HY-115867). GSK852 is a BET inhibitor targeting BD2 (pIC50=7.9)[1].